Nuva Pharmaceuticals Inc. reported unaudited consolidated earnings results for the quarter ended September 30, 2013. For the quarter, the company reported net loss before other items of CAD 169,443 compared to CAD 26,404 for the same period a year ago. Comprehensive loss was CAD 150,333 or CAD 0.01 per basic and diluted share compared to comprehensive income of CAD 880,519 or CAD 0.12 per basic and diluted share last year.

Cash outflow from operating activities was CAD 38,075 against cash inflow used in operating activities of CAD 13,523 a year ago.